|
[1]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
|
|
[2]LLOVET JM,REAL MI,MONTANA X,et al.Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma:a randomised controlled trial[J].Lancet,2002,359(9319):1734-1739.
|
|
[3]LO CM,NGAN H,TSO WK,et al.Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma[J].Hepatology,2002,35(5):1164-1171.
|
|
[4] CAMMA C,SCHEPIS F,ORLANDO A,et al.Transarterial chemoembolization for unresectable hepatocellular carcinoma:meta-analysis of randomized controlled trials[J].Radiology,2002,224(1):47-54.
|
|
[5]LLOVET JM,BRUIX J.Systematic review of randomized trials for unresectable hepatocellular carcinoma:chemoembolization improves survival[J].Hepatology,2003,37(2):429-442.
|
|
[6] BRUIX J,SHERMAN M,American Association for the Study of Liver Diseases.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022.
|
|
[7]European Association for the Study of the Liver,European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].JHepatol,2012,56(4):908-943.
|
|
[8]LUO Y,SHE DL,XIONG H,et al.Pretreatment neutrophil to lymphocyte ratio as a prognostic predictor of urologic tumors:a systematic review and meta-analysis[J].Medicine(Baltimore),2015,94(40):e1670.
|
|
[9] SUN W,ZHANG L,LUO M,et al.Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma:neutrophil-lymphocyte ratio and platelet-lymphocyte ratio[J].Head Neck,2016,38(Suppl 1):e1332-e1340.
|
|
[10]TURNER N,WONG HL,TEMPLETON A,et al.Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria[J].Int J Cancer,2016,138(3):671-678.
|
|
[11] WU G,YAO Y,BAI C,et al.Combination of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio is a useful prognostic factor in advanced non-small cell lung cancer patients[J].Thorac Cancer,2015,6(3):275-287.
|
|
[12] YODYING H,MATSUDA A,MIYASHITA M,et al.Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-tolymphocyte ratio in oncologic outcomes of esophageal cancer:a systematic review and meta-analysis[J].Ann Surg Oncol,2016,23(2):646-654.
|
|
[13]HUANG ZL,LUO J,CHEN MS,et al.Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization[J].J Vasc Interv Radiol,2011,22(5):702-709.
|
|
[14]MANO Y,SHIRABE K,YAMASHITA Y,et al.Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma:a retrospective analysis[J].Ann Surg,2013,258(2):301-305.
|
|
[15]MOTOMURA T,SHIRABE K,MANO Y,et al.Neutrophil-lymphocyte ratio reflects hepatocellular carcinoma recurrence after liver transplantation via inflammatory microenvironment[J].J Hepatol,2013,58(1):58-64.
|
|
[16]PINATO DJ,SHARMA R.An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma[J].Transl Res,2012,160(2):146-152.
|
|
[17]SULLIVAN KM,GROESCHL RT,TURAGA KK,et al.Neutrophil-to-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma:a Western perspective[J].J Surg Oncol,2014,109(2):95-97.
|
|
[18]BRUIX J,REIG M,RIMOLA J,et al.Clinical decision making and research in hepatocellular carcinoma:pivotal role of imaging techniques[J].Hepatology,2011,54(6):2238-2244.
|
|
[19] TEMPLETON AJ,MCNAMARA MG,SERUGA B,et al.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors:a systematic review and meta-analysis[J].J Natl Cancer Inst,2014,106(6):dju124.
|
|
[20] LOI S,SIRTAINE N,PIETTE F,et al.Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicinbased chemotherapy:BIG 02-98[J].J Clin Oncol,2013,31(7):860-867.
|
|
[21]NEAGOE PE,BRKOVIC A,HAJJAR F,et al.Expression and release of angiopoietin-1 from human neutrophils:intracellular mechanisms[J].Growth Factors,2009,27(6):335-344.
|
|
[22]GONG Y,KOH DR.Neutrophils promote inflammatory angiogenesis via release of preformed VEGF in an in vivo corneal model[J].Cell Tissue Res,2010,339(2):437-448.
|
|
[23]FU SJ,SHEN SL,LI SQ,et al.Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy[J].Med Oncol,2013,30(4):721.
|
|
[24]GOMEZ D,FARID S,MALIK HZ,et al.Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma[J].World J Surg,2008,32(8):1757-1762.
|
|
[25]LAI Q,CASTRO SANTA E,RICO JURI JM,et al.Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer[J].Transpl Int,2014,27(1):32-41.
|
|
[26]XIAO GQ,LIU C,LIU DL,et al.Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation[J].World J Gastroenterol,2013,19(45):8398-8407.
|
|
[27] WANG GY,YANG Y,LI H,et al.A scoring model based on neutrophil to lymphocyte ratio predicts recurrence of HBV-associated hepatocellular carcinoma after liver transplantation[J].PLo S One,2011,6(9):e25295.
|
|
[28]BERTUZZO VR,CESCON M,RAVAIOLI M,et al.Analysis of factors affecting recurrence of hepatocellular carcinoma after liver transplantation with a special focus on inflammation markers[J].Transplantation,2011,91(11):1279-1285.
|
|
[29] FAN W,ZHANG Y,WANG Y,et al.Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization[J].PLo S One,2015,10(3):e0119312.
|
|
[30]MCNALLY ME,MARTINEZ A,KHABIRI H,et al.Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization[J].Ann Surg Oncol,2013,20(3):923-928.
|
|
[31] ZHENG YB,ZHAO W,LIU B,et al.The blood neutrophil-tolymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib[J].Asian Pac J Cancer Prev,2013,14(9):5527-5531.
|
|
[32]LI X,CHEN ZH,MA XK,et al.Neutrophil-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma[J].Tumour Biol,2014,35(11):11057-11063.
|
|
[33] OH BS,JANG JW,KWON JH,et al.Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma[J].BMC Cancer,2013,13(1):78.
|
|
[34]HARIMOTO N,SHIRABE K,NAKAGAWARA H,et al.Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation:with special reference to neutrophil/lymphocyte ratio[J].Transplantation,2013,96(11):1008-1012.
|
|
[35]HALAZUN KJ,HARDY MA,RANA AA,et al.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J].Ann Surg,2009,250(1):141-151.
|
|
[36] XIAO WK,CHEN D,LI SQ,et al.Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma:a meta-analysis[J].BMC Cancer,2014,14(1):117.
|
|
[37]KUDO M,IMANAKA K,CHIDA N,et al.Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma[J].Eur JCancer,2011,47(14):2117-2127.
|
|
[38] LENCIONI R,LLOVET JM,HAN G,et al.Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC:the SPACE trial[J].J Hepatol,2016,64(5):1090-1098.
|
DownLoad: